Intellia Therapeutics Quarterly Income Statements Chart
Quarterly
|
Annual
Intellia Therapeutics Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| collaboration revenue | 14,245,000 | 16,627,000 | 9,111,000 | 6,957,000 | 28,935,000 | 11,992,000 | 13,594,000 | 12,606,000 | 13,266,000 | 14,030,000 | 11,252,000 | 12,854,000 | 7,204,000 | 6,550,000 | 6,445,000 | 6,595,000 | 22,220,000 | 16,263,000 | 12,916,000 | 10,936,000 | 10,616,000 | 11,118,000 | 10,433,000 | 7,880,000 | 7,408,000 | 7,677,000 | 7,469,000 | 6,668,000 | 7,317,000 | 5,917,000 | 6,215,000 | 2,713,000 | 4,869,000 | 4,206,000 | 1,777,000 |
| yoy | -50.77% | 38.65% | -32.98% | -44.81% | 118.11% | -14.53% | 20.81% | -1.93% | 84.15% | 114.20% | 74.58% | 94.91% | -67.58% | -59.72% | -50.10% | -39.69% | 109.31% | 46.28% | 23.80% | 38.78% | 43.30% | 44.82% | 39.68% | 18.18% | 1.24% | 29.74% | 20.18% | 145.78% | 50.28% | 40.68% | 249.75% | ||||
| qoq | -14.33% | 82.49% | 30.96% | -75.96% | 141.29% | -11.78% | 7.84% | -4.98% | -5.45% | 24.69% | -12.46% | 78.43% | 9.98% | 1.63% | -2.27% | -70.32% | 36.63% | 25.91% | 18.11% | 3.01% | -4.52% | 6.57% | 32.40% | 6.37% | -3.50% | 2.78% | 12.01% | -8.87% | 23.66% | -4.79% | 129.08% | -44.28% | 15.76% | 136.69% | |
| operating expenses: | |||||||||||||||||||||||||||||||||||
| research and development | 97,035,000 | 108,427,000 | 123,380,000 | 114,207,000 | 111,847,000 | 113,696,000 | 115,276,000 | 97,116,000 | 96,651,000 | 90,199,000 | 133,095,000 | 71,161,000 | 60,486,000 | 58,884,000 | 39,276,000 | 38,231,000 | 39,756,000 | 37,771,000 | 34,650,000 | 31,731,000 | 27,513,000 | 25,460,000 | 23,709,000 | 19,918,000 | 23,237,000 | 23,467,000 | 22,493,000 | 21,170,000 | 17,481,000 | 15,565,000 | 13,431,000 | -19,404,000 | 7,861,000 | 7,423,000 | 5,225,000 |
| general and administrative | 27,206,000 | 29,007,000 | 30,501,000 | 31,793,000 | 31,091,000 | 29,403,000 | 30,652,000 | 27,448,000 | 22,145,000 | 22,132,000 | 22,403,000 | 22,108,000 | 18,711,000 | 16,683,000 | 13,594,000 | 10,763,000 | 10,566,000 | 11,526,000 | 11,314,000 | 8,976,000 | 8,431,000 | 13,118,000 | 10,533,000 | 8,708,000 | 8,270,000 | 7,805,000 | 7,406,000 | 10,213,000 | 5,711,000 | 6,369,000 | 5,732,000 | -9,301,000 | 4,705,000 | 3,729,000 | 3,246,000 |
| total operating expenses | 124,241,000 | 137,434,000 | 153,881,000 | 146,000,000 | 142,938,000 | 143,099,000 | 145,928,000 | 124,564,000 | 118,796,000 | 112,331,000 | 155,498,000 | 93,269,000 | 79,197,000 | 75,567,000 | 52,870,000 | 48,994,000 | 50,322,000 | 49,297,000 | 45,964,000 | 40,707,000 | 35,944,000 | 38,578,000 | 34,242,000 | 28,626,000 | 31,507,000 | 31,272,000 | 29,899,000 | 31,383,000 | 23,192,000 | 21,934,000 | 19,163,000 | -22,650,000 | 12,566,000 | 11,152,000 | 8,471,000 |
| operating income | -109,996,000 | -120,807,000 | -144,770,000 | -139,043,000 | -114,003,000 | -131,107,000 | -132,334,000 | -111,958,000 | -105,530,000 | -98,301,000 | -144,246,000 | -80,415,000 | -71,993,000 | -69,017,000 | -46,425,000 | -42,399,000 | -28,102,000 | -33,034,000 | -33,048,000 | -29,771,000 | -25,328,000 | -27,460,000 | -23,809,000 | -20,746,000 | -24,099,000 | -23,595,000 | -22,430,000 | -24,715,000 | -15,875,000 | -16,017,000 | -12,948,000 | 11,798,000 | -7,697,000 | -6,946,000 | -6,694,000 |
| yoy | -3.51% | -7.86% | 9.40% | 24.19% | 8.03% | 33.37% | -8.26% | 39.23% | 46.58% | 42.43% | 210.71% | 89.66% | 156.18% | 108.93% | 40.48% | 42.42% | 10.95% | 20.30% | 38.80% | 43.50% | 5.10% | 16.38% | 6.15% | -16.06% | 51.80% | 47.31% | 73.23% | -309.48% | 106.25% | 130.59% | 93.43% | ||||
| qoq | -8.95% | -16.55% | 4.12% | 21.96% | -13.05% | -0.93% | 18.20% | 6.09% | 7.35% | -31.85% | 79.38% | 11.70% | 4.31% | 48.66% | 9.50% | 50.88% | -14.93% | -0.04% | 11.01% | 17.54% | -7.76% | 15.33% | 14.76% | -13.91% | 2.14% | 5.19% | -9.25% | 55.69% | -0.89% | 23.70% | -209.75% | -253.28% | 10.81% | 3.76% | |
| operating margin % | -772.17% | -726.57% | -1588.96% | -1998.61% | -394.00% | -1093.29% | -973.47% | -888.13% | -795.49% | -700.65% | -1281.96% | -625.60% | -999.35% | -1053.69% | -720.33% | -642.90% | -126.47% | -203.12% | -255.87% | -272.23% | -238.58% | -246.99% | -228.21% | -263.27% | -325.31% | -307.35% | -300.31% | -370.65% | -216.96% | -270.69% | -208.33% | 434.87% | -158.08% | -165.15% | -376.70% |
| other income, net: | |||||||||||||||||||||||||||||||||||
| interest income | 7,402,000 | 8,603,000 | 12,122,000 | 12,422,000 | 12,632,000 | 12,740,000 | 12,653,000 | 11,980,000 | 1,945,000 | 703,000 | 540,000 | 503,000 | 349,000 | 211,000 | 220,000 | 207,000 | 262,000 | 641,000 | 1,242,000 | 1,495,000 | 1,694,000 | 1,777,000 | 1,869,000 | 1,680,000 | 1,397,000 | 1,376,000 | 1,074,000 | 752,000 | 519,000 | 424,000 | 317,000 | 66,500 | 215,000 | 46,000 | 5,000 |
| change in fair value of investments | 1,339,000 | -2,125,000 | -3,064,000 | -20,354,000 | -6,065,000 | ||||||||||||||||||||||||||||||
| total other income | 8,741,000 | 6,478,000 | 9,058,000 | -7,932,000 | 6,567,000 | 8,883,000 | 8,653,000 | 8,832,000 | -7,699,000 | -2,377,000 | -2,626,000 | ||||||||||||||||||||||||
| net income | -101,255,000 | -114,329,000 | -135,712,000 | -146,975,000 | -107,436,000 | -122,224,000 | -123,681,000 | -103,126,000 | -113,229,000 | -100,678,000 | -146,872,000 | -81,237,000 | -71,644,000 | -68,806,000 | -46,205,000 | -42,192,000 | -27,840,000 | -32,393,000 | -31,806,000 | -28,276,000 | -23,634,000 | -25,683,000 | -21,940,000 | -19,066,000 | -22,702,000 | -22,219,000 | -21,356,000 | -23,963,000 | -15,356,000 | -15,593,000 | -12,631,000 | 11,532,000 | -7,482,000 | -6,900,000 | -6,689,000 |
| yoy | -5.75% | -6.46% | 9.73% | 42.52% | -5.12% | 21.40% | -15.79% | 26.94% | 58.04% | 46.32% | 217.87% | 92.54% | 157.34% | 112.41% | 45.27% | 49.21% | 17.80% | 26.13% | 44.97% | 48.31% | 4.11% | 15.59% | 2.73% | -20.44% | 47.84% | 42.49% | 69.08% | -307.80% | 105.24% | 125.99% | 88.83% | ||||
| qoq | -11.44% | -15.76% | -7.66% | 36.80% | -12.10% | -1.18% | 19.93% | -8.92% | 12.47% | -31.45% | 80.79% | 13.39% | 4.12% | 48.91% | 9.51% | 51.55% | -14.06% | 1.85% | 12.48% | 19.64% | -7.98% | 17.06% | 15.07% | -16.02% | 2.17% | 4.04% | -10.88% | 56.05% | -1.52% | 23.45% | -209.53% | -254.13% | 8.43% | 3.15% | |
| net income margin % | -710.81% | -687.61% | -1489.54% | -2112.62% | -371.30% | -1019.21% | -909.82% | -818.07% | -853.53% | -717.59% | -1305.30% | -632.00% | -994.50% | -1050.47% | -716.91% | -639.76% | -125.29% | -199.18% | -246.25% | -258.56% | -222.63% | -231.00% | -210.29% | -241.95% | -306.45% | -289.42% | -285.93% | -359.37% | -209.87% | -263.53% | -203.23% | 425.06% | -153.67% | -164.05% | -376.42% |
| net income per share | -0.98 | -1.1 | -1.34 | -1.52 | -1.12 | -1.38 | -1.4 | -1.17 | -1.49 | -1.33 | -1.96 | -1.1 | -0.97 | -1.01 | -0.69 | -0.7 | -0.47 | -0.61 | -0.63 | -0.58 | -0.49 | -0.56 | -0.49 | -0.43 | -0.53 | -0.52 | -0.51 | -0.63 | -0.44 | -0.45 | -0.36 | -10.39 | -0.22 | -0.36 | -9.89 |
| weighted-average shares outstanding, basic and diluted | 103,732 | 103,500 | 101,002 | 96,975 | 95,502 | 88,645 | 88,185 | 87,772 | 76,047 | 75,823 | 74,751 | 70,894 | 73,706 | 68,164 | 67,183 | 55,987 | 58,754 | 53,369 | 50,491 | 47,247 | 48,554 | 45,814 | 45,234 | 43,069 | 43,161 | 42,836 | 42,043 | 36,006 | 35,189 | 34,916 | 34,723 | 34,316 | 19,121 | 676 | |
| other comprehensive loss: | |||||||||||||||||||||||||||||||||||
| unrealized gain on marketable securities | -404 | 452 | 4,452 | -208 | -821 | 142 | -1,482 | 2,989 | 991 | -13 | -30 | -124 | -218 | 112 | -75 | 81 | 196 | 87 | |||||||||||||||||
| comprehensive loss | -101,659 | -113,877 | -131,260 | -147,183 | -108,257 | -121,928 | -124,871 | -98,343 | -113,043 | -102,170 | -152,302 | -83,695 | -71,805 | -68,807 | -46,218 | -42,222 | -27,964 | -32,611 | -31,694 | -28,351 | -23,553 | -25,487 | -21,853 | ||||||||||||
| income from equity method investment | -3,857,000 | -4,000,000 | -3,048,000 | -1,834,000 | -3,252,000 | -2,745,000 | |||||||||||||||||||||||||||||
| change in fair value of contingent consideration | -100,000 | -7,810,000 | 172,000 | -421,000 | |||||||||||||||||||||||||||||||
| other comprehensive income: | |||||||||||||||||||||||||||||||||||
| other comprehensive gain from equity method investment | 154 | 292 | 1,794 | ||||||||||||||||||||||||||||||||
| other comprehensive gain: | |||||||||||||||||||||||||||||||||||
| including the following revenue from related party | 1,946 | 5,792 | 4,935 | 4,414 | 7,767 | 5,384 | 69.25 | 277 | |||||||||||||||||||||||||||
| other comprehensive income from equity method investment | -805 | -560 | -302 | ||||||||||||||||||||||||||||||||
| unrealized loss on marketable securities | -932 | -5,128 | -43.75 | -161 | -1 | ||||||||||||||||||||||||||||||
| income before income taxes | 11,532,000 | -7,482,000 | -6,900,000 | -6,689,000 | |||||||||||||||||||||||||||||||
| income tax benefit | |||||||||||||||||||||||||||||||||||
| net income per common unit, basic and diluted | |||||||||||||||||||||||||||||||||||
| weighted-average common units outstanding, basic and diluted | |||||||||||||||||||||||||||||||||||
| benefit from income taxes |
We provide you with 20 years income statements for Intellia Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Intellia Therapeutics stock. Explore the full financial landscape of Intellia Therapeutics stock with our expertly curated income statements.
The information provided in this report about Intellia Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.